Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed director

Amylyx Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/04/2023 SC 13D/A Morningside Venture Investments Ltd reports a 3.4% stake in Amylyx Pharmaceuticals, Inc.
08/24/2023 4 FRATES JAMES M (CFO) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Exercised 18,165 options to buy @ $6.88, valued at $125k
08/17/2023 4 Morningside Venture Investments Ltd (10% Owner) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Gifted 2,000,000 shares @ $0
08/17/2023 SC 13D/A Morningside Venture Investments Ltd reports a 6.9% stake in Amylyx Pharmaceuticals, Inc.
08/17/2023 4 Mazzariello Gina (Chief Legal Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Sold 6,164 shares @ $20.8771, valued at $128.7k
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/10/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results ˗ Second quarter 2023 product revenue of $98.2 million; demand and insurance coverage for RELYVRIO® in U.S. and ALBRIOZA™ in Canada continued to grow ˗ Strong financial position supported by $22.1 million of net income during the second quarter of 2023 and cash, cash equivalents and short-term investments of $357.3 million at June 30, 2023 ˗ Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
07/26/2023 8-K Quarterly results
07/14/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/12/2023 4 Firestone Karen (Director) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Granted 3,908 options to buy @ $26.25, valued at $102.6k
06/12/2023 4 MILNE GEORGE M JR (Director) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Granted 16,985 options to buy @ $26.25, valued at $445.9k
06/12/2023 4 Quimi Daphne (Director) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Granted 16,985 options to buy @ $26.25, valued at $445.9k
06/12/2023 4 FONTEYNE PAUL R. (Director) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Granted 16,985 options to buy @ $26.25, valued at $445.9k
06/09/2023 SC 13G GOLDMAN SACHS GROUP INC reports a 5.4% stake in AMYLYX PHARMACEUTICALS, INC.
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/24/2023 4 Olinger Margaret (Chief Commercial Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Gifted 1,580 shares @ $0
05/19/2023 4 Mazzariello Gina (Chief Legal Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Gifted 500 shares @ $0
05/18/2023 4 FRATES JAMES M (CFO) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Sold 32,000 shares @ $26.9266, valued at $861.7k
Sold 500 shares @ $27.6, valued at $13.8k
Exercised 32,500 options to buy @ $6.88, valued at $223.6k
05/17/2023 4 Yeramian Patrick D (Chief Medical Officer) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Sold 11,965 shares @ $29.0312, valued at $347.4k
Exercised 2,201 options to buy @ $0.37, valued at $814.4
Exercised 9,764 options to buy @ $6.88, valued at $67.2k
05/16/2023 144 Form 144 - Report of proposed sale of securities:
05/15/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results ˗ First quarter 2023 product revenue of $71.4 million; commercial launches of RELYVRIO® in U.S. and ALBRIOZA™ in Canada for the treatment of ALS continue to progress ˗ Regulatory review ongoing in the EU ˗ Expansion of pipeline with first participant dosed in Phase 2 HELIOS study of AMX0035 in Wolfram syndrome and planned initiation of a pivotal Phase 3 study in progressive supranuclear palsy anticipated this year ˗ Management to host conference call and webcast today at 4:30 p.m. Eastern Time"
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/26/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
04/26/2023 3/A Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
04/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 SC 13D/A Morningside Venture Investments Ltd reports a 12.9% stake in Amylyx Pharmaceuticals, Inc.
03/31/2023 4 Morningside Venture Investments Ltd (10% Owner) has filed a Form 4 on Amylyx Pharmaceuticals, Inc.
Txns: Sold 29,048 shares @ $30.45, valued at $884.5k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy